Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old...
Day: June 18, 2025
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company...
Rockefeller Foundation Adds Govind Iyer to Board of Trustees
NEW YORK, June 18, 2025 /PRNewswire/ -- The Rockefeller Foundation is pleased to announce that Mr. Govind Iyer, global business...
Caris Life Sciences Announces Pricing of Initial Public Offering
IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision...